JP2012507535A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507535A5
JP2012507535A5 JP2011534624A JP2011534624A JP2012507535A5 JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5 JP 2011534624 A JP2011534624 A JP 2011534624A JP 2011534624 A JP2011534624 A JP 2011534624A JP 2012507535 A5 JP2012507535 A5 JP 2012507535A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
hydrogen
fluoro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011534624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507535A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/061573 external-priority patent/WO2010062507A1/en
Publication of JP2012507535A publication Critical patent/JP2012507535A/ja
Publication of JP2012507535A5 publication Critical patent/JP2012507535A5/ja
Pending legal-status Critical Current

Links

JP2011534624A 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト Pending JP2012507535A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11070308P 2008-11-03 2008-11-03
US61/110,703 2008-11-03
PCT/US2009/061573 WO2010062507A1 (en) 2008-11-03 2009-10-22 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
JP2012507535A JP2012507535A (ja) 2012-03-29
JP2012507535A5 true JP2012507535A5 (show.php) 2012-12-13

Family

ID=41566219

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534624A Pending JP2012507535A (ja) 2008-11-03 2009-10-22 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (29)

Country Link
US (1) US8404687B2 (show.php)
EP (1) EP2364185B1 (show.php)
JP (1) JP2012507535A (show.php)
KR (1) KR101335746B1 (show.php)
CN (1) CN102202737B (show.php)
AU (1) AU2009320251C1 (show.php)
BR (1) BRPI0921437A2 (show.php)
CA (1) CA2742539C (show.php)
CL (1) CL2011000979A1 (show.php)
CO (1) CO6382123A2 (show.php)
CR (1) CR20110202A (show.php)
CY (1) CY1114023T1 (show.php)
DK (1) DK2364185T3 (show.php)
EA (1) EA018931B1 (show.php)
EC (1) ECSP11011021A (show.php)
ES (1) ES2418479T3 (show.php)
HR (1) HRP20130527T1 (show.php)
IL (1) IL211841A0 (show.php)
MA (1) MA32726B1 (show.php)
MX (1) MX2011004683A (show.php)
NZ (1) NZ591945A (show.php)
PE (1) PE20110433A1 (show.php)
PL (1) PL2364185T3 (show.php)
PT (1) PT2364185E (show.php)
SI (1) SI2364185T1 (show.php)
TN (1) TN2011000166A1 (show.php)
UA (1) UA102115C2 (show.php)
WO (1) WO2010062507A1 (show.php)
ZA (1) ZA201102448B (show.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809193A2 (pt) * 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
PT2358698E (pt) 2008-11-17 2012-10-24 Lilly Co Eli Antagonistas da via hedgehog de piridazina tetrasubstituída
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
AU2021360767A1 (en) 2020-10-13 2023-04-27 Endeavor Biomedicines, Inc. Methods of treating fibrosis
EP4590672A1 (en) * 2022-09-23 2025-07-30 Merck Sharp & Dohme LLC Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
EP0876366B1 (en) 1996-01-15 2001-07-25 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
KR100622323B1 (ko) * 1996-10-01 2006-11-30 교와 핫꼬 고교 가부시끼가이샤 질소-함유헤테로고리화합물
US6432970B2 (en) 1998-04-09 2002-08-13 Johns Hopkins University School Of Medicine Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
GB0013674D0 (en) 1999-06-08 2000-07-26 Lorantis Ltd Therapeutic use
DE60322869D1 (de) 2002-04-22 2008-09-25 Univ Johns Hopkins Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
US7888364B2 (en) * 2004-09-02 2011-02-15 Curis, Inc. Pyridyl inhibitors of hedgehog signalling
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
BRPI0809193A2 (pt) 2007-03-15 2014-09-23 Novartis Ag Compostos orgânicos e seus usos
EP2170866B1 (en) * 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
CA2697682A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inapropriate hedgehog signalling
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
PT2358698E (pt) 2008-11-17 2012-10-24 Lilly Co Eli Antagonistas da via hedgehog de piridazina tetrasubstituída
US8445493B2 (en) 2008-11-17 2013-05-21 Eli Lilly And Company Tetrasubstituted pyridazines hedgehog pathway antagonists
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012507535A5 (show.php)
JP2012530705A5 (show.php)
JP2012509263A5 (show.php)
JP2011529054A5 (show.php)
JP2014515013A5 (show.php)
JP2016503786A5 (show.php)
JP2011527666A5 (show.php)
JP2011519854A5 (show.php)
JP2015512931A5 (show.php)
JP2011528658A5 (show.php)
JP2012533546A5 (show.php)
JP2009545527A5 (show.php)
JP2010513478A5 (show.php)
JP2010533722A5 (show.php)
JP2013543896A5 (show.php)
JP2009535462A5 (show.php)
JP2006526031A5 (show.php)
JP2009502743A5 (show.php)
JP2013523733A5 (show.php)
JP2011527332A5 (show.php)
JP2010521516A5 (show.php)
JP2015531774A5 (show.php)
JP2015501799A5 (show.php)
JP2008513510A5 (show.php)
JP2013506674A5 (show.php)